# OnCo record cr-002 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cr-002/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cr-002" ;
  schema:name "CR-002"@en ;
  schema:description "CR-002 is an experimental antibody-drug conjugate from Crescent Biopharma, in phase 1 trials for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours."@en ;
  schema:url <https://onco.cc/drugs/cr-002/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.crescentbiopharma.com/pipeline>, <https://www.crescentbiopharma.com/pipeline>, <https://clinicaltrials.gov/api/v2/studies/NCT07909031>, <https://clinicaltrials.gov/search?intr=CR-002> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Antibody-drug conjugate (topoisomerase inhibitor payload)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/crescent-biopharma/> ;
  onco:trials <https://onco.cc/trials/nct07909031/> .